Time to Treatment Prediction in Chronic Lymphocytic Leukemia Based on New Transcriptional Patterns

被引:7
|
作者
Mosquera Orgueira, Adrian [1 ,2 ,3 ]
Antelo Rodriguez, Beatriz [1 ,2 ,3 ]
Alonso Vence, Natalia [1 ,2 ]
Bendana Lopez, Angeles [1 ,2 ]
Diaz Arias, Jose Angel [1 ,2 ]
Diaz Varela, Nicolas [2 ]
Gonzalez Perez, Marta Sonia [1 ,2 ]
Perez Encinas, Manuel Mateo [1 ,3 ]
Bello Lopez, Jose Luis [1 ,2 ,3 ]
机构
[1] Hlth Res Inst Santiago de Compostela IDIS, Santiago De Compostela, Spain
[2] Complexo Hosp Univ Santiago de Compostela, Div Hematol, SERGAS, Santiago De Compostela, Spain
[3] Univ Santiago de Compostela, Dept Med, Santiago De Compostela, Spain
来源
FRONTIERS IN ONCOLOGY | 2019年 / 9卷
基金
日本学术振兴会;
关键词
chronic lymphocytic leukemia; time to treatment prediction; gene expression; RNAseq; machine learning; prognostic factors; IGHV; LYMPHOMA;
D O I
10.3389/fonc.2019.00079
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic lymphocytic leukemia (CLL) is the most frequent lymphoproliferative syndrome in western countries. CLL evolution is frequently indolent, and treatment is mostly reserved for those patients with signs or symptoms of disease progression. In this work, we used RNA sequencing data from the International Cancer Genome Consortium CLL cohort to determine new gene expression patterns that correlate with clinical evolution.We determined that a 290-gene expression signature, in addition to immunoglobulin heavy chain variable region (IGHV) mutation status, stratifies patients into four groups with notably different time to first treatment. This finding was confirmed in an independent cohort. Similarly, we present a machine learning algorithm that predicts the need for treatment within the first 5 years following diagnosis using expression data from 2,198 genes. This predictor achieved 90% precision and 89% accuracy when classifying independent CLL cases. Our findings indicate that CLL progression risk largely correlates with particular transcriptomic patterns and paves the way for the identification of high-risk patients who might benefit from prompt therapy following diagnosis.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma
    Barrientos, Jacqueline C.
    FUTURE ONCOLOGY, 2016, 12 (18) : 2077 - 2094
  • [42] Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US
    Yang, Xiaoqin
    Zanardo, Enrico
    Lejeune, Dominique
    De Nigris, Enrico
    Sarpong, Eric
    Farooqui, Mohammed
    Laliberte, Francois
    ONCOLOGIST, 2024, 29 (03) : E360 - E371
  • [43] Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia
    Tausch, Eugen
    Mertens, Daniel
    Stilgenbauer, Stephan
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (1-2) : 34 - 40
  • [44] Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies
    Mato, Anthony R.
    Samp, Jennifer C.
    Gauthier, Genevieve
    Terasawa, Emi
    Brander, Danielle M.
    CANCER BIOLOGY & THERAPY, 2018, 19 (07) : 636 - 643
  • [45] CpG island methylation patterns in chronic lymphocytic leukemia
    Seeliger, Barbara
    Wilop, Stefan
    Osieka, Rainhardt
    Galm, Oliver
    Jost, Edgar
    LEUKEMIA & LYMPHOMA, 2009, 50 (03) : 419 - 426
  • [46] Chronic lymphocytic leukemia treatment based on the results of recent clinical trials
    Szmigielska-Kaplon, Anna
    Robak, Tadeusz
    ONCOLOGY IN CLINICAL PRACTICE, 2005, 1 (03): : 141 - 150
  • [47] Treatment of Richter Transformation of Chronic Lymphocytic Leukemia in the Modern Era
    Briski, Robert
    Taylor, Justin
    CANCERS, 2023, 15 (06)
  • [48] Identification of a novel resistance mechanism in venetoclax treatment and its prediction in chronic lymphocytic leukemia
    Takacs, Ferenc
    Mikala, Gabor
    Nagy, Noemi
    Reszegi, Andrea
    Czeti, Agnes
    Szaloki, Gabor
    Barna, Gabor
    ACTA ONCOLOGICA, 2021, 60 (04) : 528 - 530
  • [49] Subtotal splenectomy for the treatment of chronic lymphocytic leukemia
    Andy Petroianu
    Annals of Hematology, 2003, 82 : 708 - 709
  • [50] Venetoclax for the treatment of patients with chronic lymphocytic leukemia
    Crombie, Jennifer
    Davids, Matthew S.
    FUTURE ONCOLOGY, 2017, 13 (14) : 1223 - 1232